*仅供医学专业人士阅读参考
埃万妥单抗联合兰泽替尼方案正式获得NMPA批准，成为中国EGFR敏感突变晚期一线治疗新增选择。
*以下内容仅供医疗卫生专业人士浏览。
参考文献：
[1]Cho BC， Lu S， Felip E， et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498.
[2]Lu S， Byoung CC， Jong-Seok L， et al. Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated， Advanced Non-small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis. 2023 ESMO Aisa. LBA10.
[3]Cho BC， Lu S， Felip E， et al. Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study. 2025 ELCC. 4O.
[4]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small cell LungCancer Version 7.2025.
[5]中国临床肿瘤学会（CSCO）非小细胞肺癌（NSCLC）诊疗指南（2025年）
[6]Cho BC， Lu S， Felip E， et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498.
[7]Spira AI， Paz-Ares L， Han JY， et al. Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr，a Phase 2 Study:A Brief Report.J Thorac Oncol. Published online January 24，2025.
[8]Nicolas G， Li WM， Alexander lS， et al.Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib:Early success of the COCOON trial.2025 ELCC. 10MO.
[9]Feldman JL， Cho BC， Li W， et al. Dermatologic prophylaxis and impact on patient-reported outcomes in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial. 2025 ASCO. Abstract 8641.
审批编号：CP-551633 审批时间：11/11/2025 过期时间：11/11/2026
*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场。
元鼎证券_元鼎证券正规实盘交易_十大配资平台app下载提示：本文来自互联网，不代表本网站观点。